Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6709-6715

  Herbertson, Rebecca A ^a   Tebbutt, Niall C ^a   Lee, Fook Thean ^a   MacFarlane, David J ^b   Chappell, Bridget ^a   Micallef, Noel ^a   Lee, Sze Ting ^a   Saunder, Timothy ^a   Hopkins, Wendie ^a   Smyth, Fiona E ^a   Wyld, David K ^b   Bellen, John ^b   Sonnichsen, Daryl S ^c   Brechbiel, Martin W ^d   Murone, Carmel ^a   Scott, Andrew M ^a  

^a AUSTIN HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c PFIZER INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CALICHEAMICIN; CMD 193; FLUORODEOXYGLUCOSE F 18; HUMAN MONOCLONAL ANTIBODY; INDIUM 111; LE(Y) ANTIGEN; MONOCLONAL ANTIBODY HU3S193; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BLOATING; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGASTRIC DISCOMFORT; EPISTAXIS; ERYTHEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FLUSHING; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERBILIRUBINEMIA; LETHARGY; LEUKOPENIA; LIVER FUNCTION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOASSAY; SCINTILLATION CAMERA; SIDE EFFECT; STOMACH CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOCONJUGATES; LEWIS BLOOD-GROUP SYSTEM; MALE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL;

EID: 70350712272     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0536     Document Type: Article

References (30)

1. Bross P, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7:1490-1496 (Pubitemid 32708610)
2. Dettke M, PalfiG, LoibnerH.Activation-dependent expression of the blood group-related lewis Y antigen on peripheral blood granulocytes. J Leukoc Biol 2000;68:511-514 (Pubitemid 30764583)
3. Zhang S, Zhang HS, Cordon-Cardo C, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 1997;73: 50-56 (Pubitemid 27445990)
4. Kitamura K, Stockert E, Garin-Chesa P, et al. Specificity analysis of blood group Lewis-y (Le(y)) antibodies generated against synthetic and natural Le(y) determinants. Proc Natl Acad Sci U S A 1994;91:12957-12961
5. Yin BW, Finstad CL, Kitamura K, et al. Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int J Cancer 1996;65:406-412 (Pubitemid 26083243)
6. Myers RB, Srivastava S, Grizzle WE. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma. J Urol 1995;153:1572-1574
7. Leoni F, Colnaghi M, Canevari S, et al. Glycolipids carrying Ley are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1. Int J Cancer 1992;51:225-231.
8. Baldus SE, Monig SP, Zirbes TK, et al. Lewis(y) antigen (CD174) and apoptosis in gastric and colorectal carcinomas: correlations with clinical and prognostic parameters. Histol Histopathol 2006;21:503-510
9. Zenita K, Kirihata Y, Kitahara A, et al. Fucosylated type-2 chain polylactosamine antigens in human lung cancer. Int J Cancer 1988;41:344-349 (Pubitemid 18080785)
10. Cordon-Cardo C, Lloyd KO, Sakamoto J, et al. Immunohistologic expression of blood-group antigens in normal human gastrointestinal tract and colonic carcinoma. Int J Cancer 1986;37: 667-676 (Pubitemid 16042057)
11. Sakamoto J, Furukawa K, Cordon-Cardo C, et al. Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res 1996;46:1553-1561
12. Scott AM, Geleick D, Rubira M, et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res 2000;60:3254-3261
13. Scott AM, Tebbutt N, Lee FT, et al. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3S193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res 2007;13:3286-3292
14. Krug LM ,M ilton D, Chen L, et al. Targeting Lewis Y (LeY) in small cell lung cancer (SCLC) with a humanzied monoclonal antibody, hu3S193. J Clin Oncol 2006;24:7086.
15. Boghaert ER, Sridharan L, Armellino DC, et al. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl υ calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. Clin Cancer Res 2004; 10:4538-4549 (Pubitemid 38878898)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
17. Scott AM, Lee F-T, Hopkins W, et al. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J Clin Oncol 2001;19:3976-3987
18. Liu A, Williams LE, Raubitschek AA. A CT assisted method for absolute quantitation of internal radioactivity. Med Phys 1996;23:1919-1928
19. Scott AM, Lee F-T, Jones R, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005;11:4810-4817
20. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical Tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999;35:1773-1782
21. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18FFDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059-1066 (Pubitemid 46939960)
22. Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A 2007;104:4071-4076
23. Holden SN, Beeram M, Krop IE, et al. A phase I study of weekly dosing of trasutzumab-DM1 (T-DM1) in patients with advanced Her2+ breast cancer [abstract 1029]. J Clin Oncol 26:2008 (May 20 suppl; abstr 1029).
24. Terpstra V, van Amersfoort ES, van Velzen AG, et al. Hepatic and extrahepatic scavenger receptors: function in relation to disease. Arterioscler Thromb Vasc Biol 2000;20:1860-1872 (Pubitemid 30648812)
25. Kooistra T, Duursma AM, Bouma JM, et al. Effect of size and charge on endocytosis of lysozyme derivatives by sinusoidal rat liver cells in vivo. Biochim Biophys Acta 1980;631:439-450 (Pubitemid 10022730)
26. Nishida K, Mihara K, Takino T, et al. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm Res 1991;8:437-444
27. Gillespie AM, Broadhead TJ, Chan SY, et al. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB- 401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann Oncol 2000;11:735-741
28. Chan SY, Gordon AN, Coleman RE, et al. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother 2003; 52:243-248
29. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-1452 (Pubitemid 41356159)
30. McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin- associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007;31: 599-604. (Pubitemid 46578145)